The neurotechnology
industry, all in one place.
411+ companies, funding rounds, clinical trials, and breakthroughs — tracked daily for founders, investors, and researchers.
411+
Companies tracked
across 9 categories
$18B+
Funding tracked
in VC investment
39+
News published
industry articles
Every Sunday
Weekly digest
NeuroTech Digest
Browse by category
View all 411 companies →Featured companies
COMPASS Pathways
Psychedelics
COMPASS Pathways is a mental health care company focused on accelerating patient access to psilocybin therapy, with their proprietary COMP360 psilocybin formulation in Phase 3 trials for treatment-resistant depression. They are one of the most advanced and well-funded psychedelic medicine companies globally.
Kernel
Research Tools
Kernel builds non-invasive neuroimaging helmets — the Flow (TD-fNIRS) and Flux (MEG) systems — designed to make high-resolution brain scanning accessible outside of hospital settings. Founded by Bryan Johnson, the company aims to democratize neuroscience research and brain measurement at scale.
MindMed
Psychedelics
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
Neuralink
Brain-Computer Interfaces
Neuralink develops ultra-high-bandwidth brain-machine interfaces with the goal of merging human cognition with AI. Their flagship N1 implant uses thousands of electrodes to record and stimulate neural activity, with the first human trial participant demonstrated cursor control via thought in 2024.
Recently added
Funding spotlight
Adeption
Private
AdTonos
Private
Advanced Brain Monitoring
Private
Advantis Medical Imaging
Private
Adventist Health
Private
Afference, Inc.
Private
Latest news
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
Synchron raises $340M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
Synchron raises $310M Series E to scale its minimally invasive Stentrode BCI platform toward a pivotal FDA trial and commercial launch.
Synchron raises $310M Series E to scale Stentrode BCI manufacturing and pursue FDA De Novo authorization by late 2027.
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
Synchron secures $410M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
Every Sunday
The NeuroTech Digest
Funding rounds, breakthroughs, and top jobs — curated weekly for industry professionals.
Subscribe free →For companies
Reach neurotech decision-makers
Premium listings, newsletter sponsorships, and featured placements.
View packages →News & insights
All articles →
ProductIt's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
2026-06-23
FundingSynchron Closes $340M Series E to Accelerate Stentrode Commercialization in the US and EU
Synchron raises $340M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
2026-06-22
FundingSynchron Closes $310M Series E to Accelerate Stentrode BCI Commercialization
Synchron raises $310M Series E to scale its minimally invasive Stentrode BCI platform toward a pivotal FDA trial and commercial launch.
2026-06-19
FundingSynchron Closes $310M Series E to Accelerate Stentrode BCI Toward Commercial Clearance
Synchron raises $310M Series E to scale Stentrode BCI manufacturing and pursue FDA De Novo authorization by late 2027.
2026-06-17
FundingSynchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
2026-06-15
FundingSynchron Closes $410M Series E to Accelerate Stentrode BCI Commercialization
Synchron secures $410M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
2026-06-15
411+
Companies
across 9 sectors
$18B+
VC Invested
tracked in our database
3×/week
News published
Mon · Wed · Fri
13+
Articles
in our archive
Companies by sector
26
Brain-Computer
10
Cognitive
40
Mental
33
Neuromodulation
28
Neuropharmaceuticals
12
Neurodiagnostics
12
Research
10
Neurofeedback
40
Psychedelics
The NeuroTech Digest
Funding rounds, product launches, research breakthroughs, and the best jobs — curated weekly for the neurotech industry.
No spam. Unsubscribe anytime.